Related Experiment Video
Updated: Mar 31, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Thyroid dysfunction and dyslipidemia in chronic kidney disease patients
Saroj Khatiwada1, K C Rajendra2, Sharad Gautam3
1Department of Pharmacy, Central Institute of Science and Technology (CIST) College, Pokhara University, Kathmandu, 44600, Nepal. khatiwadasaroj22@gmail.com.
Thyroid dysfunction and abnormal lipid profiles are common in chronic kidney disease (CKD) patients. Advanced CKD stages correlate with increased risks of hypothyroidism and cardiovascular disease.
Area of Science:
- Nephrology
- Endocrinology
- Cardiology
Background:
- Chronic kidney disease (CKD) is a growing global health concern with increasing prevalence.
- CKD progression is linked to serious complications like thyroid dysfunction, dyslipidemia, and cardiovascular diseases (CVD).
Purpose of the Study:
- To investigate the prevalence of thyroid dysfunction and lipid profile abnormalities in patients with chronic kidney disease.
- To explore the relationship between CKD progression and these complications.
Main Methods:
- A cross-sectional study involving 360 CKD patients.
- Collected demographic data and medical history (diabetes, hypertension, CVD).
- Analyzed blood samples for renal function markers, thyroid hormones (T3, T4, TSH), and lipid profiles (total cholesterol, HDL, LDL, triglycerides).
Main Results:
- Thyroid dysfunction observed in 38.6% of CKD patients, primarily subclinical hypothyroidism (27.2%).
- Dyslipidemia was prevalent: hypercholesterolemia (34.4%), low HDL (34.1%), high LDL (35%), and hypertriglyceridemia (36.6%).
- Patients with Stage 4 and 5 CKD showed a significantly higher risk of thyroid dysfunction and CVD compared to Stage 3.
Conclusions:
- Thyroid dysfunction and various forms of dyslipidemia are highly prevalent in CKD patients.
- Hypothyroidism and cardiovascular disease risk increase with CKD progression.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
